Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Neoplasms | 41 | 2024 | 1439 | 5.400 |
Why?
|
Endometrial Neoplasms | 46 | 2024 | 1357 | 4.790 |
Why?
|
Leiomyosarcoma | 21 | 2024 | 424 | 3.990 |
Why?
|
Genital Neoplasms, Female | 12 | 2024 | 533 | 2.710 |
Why?
|
Sarcoma, Endometrial Stromal | 14 | 2023 | 93 | 2.670 |
Why?
|
Vulvar Neoplasms | 16 | 2023 | 263 | 2.640 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 6 | 2024 | 77 | 2.350 |
Why?
|
Fallopian Tube Neoplasms | 15 | 2020 | 328 | 2.170 |
Why?
|
Uterine Cervical Neoplasms | 30 | 2023 | 2003 | 2.150 |
Why?
|
Smooth Muscle Tumor | 8 | 2023 | 63 | 2.020 |
Why?
|
Ovarian Neoplasms | 30 | 2024 | 4878 | 2.000 |
Why?
|
Immunohistochemistry | 54 | 2024 | 11071 | 1.960 |
Why?
|
Adenosarcoma | 6 | 2021 | 36 | 1.860 |
Why?
|
Endometrial Stromal Tumors | 7 | 2023 | 46 | 1.840 |
Why?
|
Pelvic Neoplasms | 6 | 2023 | 248 | 1.840 |
Why?
|
Carcinoma, Endometrioid | 12 | 2024 | 276 | 1.780 |
Why?
|
Carcinoma in Situ | 15 | 2022 | 796 | 1.670 |
Why?
|
Cystadenocarcinoma, Serous | 17 | 2020 | 479 | 1.590 |
Why?
|
Precancerous Conditions | 13 | 2023 | 977 | 1.570 |
Why?
|
Leiomyoma | 10 | 2023 | 654 | 1.460 |
Why?
|
Polyps | 3 | 2021 | 197 | 1.270 |
Why?
|
Sarcoma | 9 | 2024 | 1786 | 1.270 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 6 | 2020 | 194 | 1.130 |
Why?
|
Teratoma | 4 | 2022 | 403 | 1.120 |
Why?
|
Endometrium | 9 | 2023 | 403 | 1.090 |
Why?
|
Carcinoma | 9 | 2023 | 2331 | 1.070 |
Why?
|
Diagnosis, Differential | 36 | 2024 | 12965 | 1.040 |
Why?
|
In Situ Hybridization, Fluorescence | 16 | 2024 | 2506 | 1.030 |
Why?
|
Endometrial Hyperplasia | 5 | 2024 | 97 | 1.030 |
Why?
|
Cervix Uteri | 8 | 2017 | 582 | 1.020 |
Why?
|
Leiomyomatosis | 2 | 2022 | 69 | 0.950 |
Why?
|
Adenocarcinoma | 19 | 2023 | 6315 | 0.950 |
Why?
|
Vaginal Neoplasms | 3 | 2020 | 104 | 0.930 |
Why?
|
Soft Tissue Neoplasms | 6 | 2024 | 1152 | 0.920 |
Why?
|
Papillomavirus Infections | 11 | 2023 | 1607 | 0.900 |
Why?
|
Mycoses | 4 | 2015 | 387 | 0.880 |
Why?
|
Candida | 5 | 2015 | 173 | 0.840 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2023 | 34 | 0.840 |
Why?
|
Wolffian Ducts | 4 | 2019 | 27 | 0.820 |
Why?
|
14-3-3 Proteins | 5 | 2017 | 221 | 0.810 |
Why?
|
Neutropenia | 8 | 2015 | 884 | 0.780 |
Why?
|
Female | 214 | 2024 | 391270 | 0.780 |
Why?
|
Uterine Diseases | 2 | 2021 | 117 | 0.780 |
Why?
|
Oncogene Proteins, Fusion | 9 | 2022 | 1596 | 0.760 |
Why?
|
Pathology, Clinical | 2 | 2022 | 375 | 0.750 |
Why?
|
Dermoid Cyst | 1 | 2021 | 92 | 0.740 |
Why?
|
Antifungal Agents | 8 | 2016 | 749 | 0.730 |
Why?
|
Gene Rearrangement | 8 | 2024 | 1122 | 0.720 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2020 | 35 | 0.710 |
Why?
|
Solitary Fibrous Tumors | 2 | 2018 | 67 | 0.690 |
Why?
|
Adenomatoid Tumor | 1 | 2019 | 12 | 0.670 |
Why?
|
Neurodermatitis | 1 | 2019 | 8 | 0.660 |
Why?
|
Sarcoma, Synovial | 1 | 2020 | 151 | 0.660 |
Why?
|
Adenomyoma | 2 | 2018 | 8 | 0.640 |
Why?
|
Middle Aged | 130 | 2024 | 220352 | 0.610 |
Why?
|
Adult | 128 | 2024 | 219994 | 0.600 |
Why?
|
Fungemia | 6 | 2001 | 58 | 0.590 |
Why?
|
Peutz-Jeghers Syndrome | 2 | 2024 | 59 | 0.590 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2017 | 43 | 0.570 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 265 | 0.560 |
Why?
|
Uterine Cervical Dysplasia | 6 | 2013 | 384 | 0.550 |
Why?
|
High-Throughput Nucleotide Sequencing | 10 | 2023 | 3616 | 0.550 |
Why?
|
Neoplasm Proteins | 13 | 2020 | 3610 | 0.550 |
Why?
|
Neuroendocrine Tumors | 1 | 2023 | 650 | 0.540 |
Why?
|
Humans | 221 | 2024 | 760621 | 0.540 |
Why?
|
Uterine Cervical Diseases | 3 | 2013 | 74 | 0.530 |
Why?
|
Aged | 96 | 2024 | 169152 | 0.530 |
Why?
|
Candidemia | 2 | 2015 | 38 | 0.530 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 3 | 2023 | 368 | 0.530 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2009 | 238 | 0.520 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2013 | 255 | 0.510 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2015 | 5649 | 0.500 |
Why?
|
Tumor Suppressor Protein p53 | 16 | 2023 | 2919 | 0.480 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2015 | 67 | 0.480 |
Why?
|
Brazil | 14 | 2015 | 1218 | 0.480 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2022 | 4024 | 0.470 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2009 | 586 | 0.470 |
Why?
|
Ki-67 Antigen | 6 | 2019 | 631 | 0.470 |
Why?
|
Prognosis | 37 | 2023 | 29658 | 0.460 |
Why?
|
Myometrium | 3 | 2013 | 176 | 0.460 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 3 | 2022 | 113 | 0.450 |
Why?
|
Biopsy | 16 | 2021 | 6771 | 0.450 |
Why?
|
Predictive Value of Tests | 25 | 2024 | 15289 | 0.440 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 611 | 0.430 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2015 | 3602 | 0.420 |
Why?
|
Amphotericin B | 4 | 2013 | 142 | 0.420 |
Why?
|
Endometriosis | 4 | 2023 | 874 | 0.400 |
Why?
|
Transcription Factors | 18 | 2024 | 12103 | 0.400 |
Why?
|
Bacteremia | 3 | 2009 | 980 | 0.400 |
Why?
|
Aged, 80 and over | 43 | 2024 | 58995 | 0.390 |
Why?
|
Fallopian Tubes | 5 | 2020 | 178 | 0.390 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2016 | 517 | 0.380 |
Why?
|
Cyclin D1 | 2 | 2013 | 451 | 0.380 |
Why?
|
RNA-Binding Protein EWS | 2 | 2024 | 210 | 0.380 |
Why?
|
Candidiasis | 5 | 2007 | 363 | 0.380 |
Why?
|
Neoplasm Staging | 17 | 2024 | 11152 | 0.380 |
Why?
|
Endodermal Sinus Tumor | 2 | 2022 | 53 | 0.370 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 494 | 0.370 |
Why?
|
Nuclear Proteins | 12 | 2024 | 5791 | 0.370 |
Why?
|
Transplantation | 1 | 2012 | 218 | 0.370 |
Why?
|
Liposarcoma | 3 | 2019 | 283 | 0.360 |
Why?
|
Immunocompromised Host | 4 | 2012 | 857 | 0.360 |
Why?
|
Gene Fusion | 3 | 2017 | 354 | 0.360 |
Why?
|
Cytomegalovirus | 1 | 2015 | 755 | 0.350 |
Why?
|
Uterus | 7 | 2023 | 651 | 0.350 |
Why?
|
DNA Helicases | 4 | 2023 | 854 | 0.350 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 1728 | 0.340 |
Why?
|
Co-Repressor Proteins | 6 | 2015 | 191 | 0.330 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1764 | 0.330 |
Why?
|
HLA Antigens | 1 | 2015 | 1368 | 0.330 |
Why?
|
Metaplasia | 5 | 2019 | 320 | 0.330 |
Why?
|
HMGA2 Protein | 3 | 2010 | 102 | 0.330 |
Why?
|
Octamer Transcription Factor-3 | 2 | 2009 | 223 | 0.330 |
Why?
|
Hematologic Neoplasms | 6 | 2012 | 1895 | 0.320 |
Why?
|
Adenofibroma | 1 | 2008 | 25 | 0.320 |
Why?
|
Lipoma | 2 | 2023 | 292 | 0.320 |
Why?
|
beta Catenin | 4 | 2024 | 1043 | 0.320 |
Why?
|
Aspergillus | 4 | 2016 | 92 | 0.310 |
Why?
|
Meninges | 1 | 2010 | 197 | 0.310 |
Why?
|
Carcinosarcoma | 2 | 2021 | 104 | 0.310 |
Why?
|
Young Adult | 25 | 2024 | 58741 | 0.310 |
Why?
|
Hamartoma | 1 | 2010 | 235 | 0.300 |
Why?
|
Trophoblastic Neoplasms | 2 | 2020 | 88 | 0.300 |
Why?
|
Adolescent | 47 | 2024 | 87810 | 0.300 |
Why?
|
Neoplasm Invasiveness | 11 | 2023 | 3618 | 0.300 |
Why?
|
Papillomaviridae | 6 | 2022 | 1117 | 0.300 |
Why?
|
Necrosis | 4 | 2022 | 1612 | 0.300 |
Why?
|
DNA Mutational Analysis | 10 | 2022 | 4107 | 0.300 |
Why?
|
Stromal Cells | 5 | 2015 | 1326 | 0.300 |
Why?
|
Observer Variation | 11 | 2021 | 2601 | 0.300 |
Why?
|
SOXB1 Transcription Factors | 1 | 2009 | 286 | 0.290 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2017 | 452 | 0.290 |
Why?
|
Carcinoma, Renal Cell | 1 | 2022 | 3218 | 0.290 |
Why?
|
Invasive Pulmonary Aspergillosis | 2 | 2017 | 17 | 0.280 |
Why?
|
Human papillomavirus 6 | 2 | 2019 | 16 | 0.280 |
Why?
|
Mitotic Index | 3 | 2016 | 161 | 0.280 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2019 | 698 | 0.280 |
Why?
|
Myxoma | 3 | 2005 | 114 | 0.280 |
Why?
|
Oncogene Fusion | 3 | 2021 | 81 | 0.270 |
Why?
|
Drug Resistance, Multiple | 1 | 2007 | 254 | 0.260 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 4312 | 0.260 |
Why?
|
Mutation | 24 | 2023 | 29932 | 0.260 |
Why?
|
Translocation, Genetic | 6 | 2012 | 1388 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2022 | 9276 | 0.240 |
Why?
|
GATA3 Transcription Factor | 2 | 2015 | 152 | 0.240 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2009 | 586 | 0.230 |
Why?
|
Aspergillosis | 3 | 2001 | 243 | 0.230 |
Why?
|
Mitosis | 2 | 2021 | 1191 | 0.220 |
Why?
|
DNA-Binding Proteins | 12 | 2023 | 9585 | 0.220 |
Why?
|
Gene Amplification | 2 | 2020 | 1085 | 0.220 |
Why?
|
Cell Proliferation | 9 | 2020 | 10446 | 0.220 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2023 | 895 | 0.220 |
Why?
|
Xerostomia | 1 | 2003 | 94 | 0.220 |
Why?
|
Neoplasm Seeding | 2 | 2013 | 84 | 0.220 |
Why?
|
Genetic Testing | 1 | 2016 | 3531 | 0.210 |
Why?
|
Adnexal Diseases | 2 | 2024 | 106 | 0.210 |
Why?
|
Fumarate Hydratase | 1 | 2022 | 52 | 0.210 |
Why?
|
Myxosarcoma | 1 | 2022 | 11 | 0.210 |
Why?
|
Myofibroblasts | 1 | 2024 | 207 | 0.200 |
Why?
|
Retrospective Studies | 29 | 2024 | 80372 | 0.200 |
Why?
|
Hysterectomy | 5 | 2015 | 904 | 0.200 |
Why?
|
Myelodysplastic Syndromes | 1 | 2012 | 1394 | 0.200 |
Why?
|
Homeodomain Proteins | 2 | 2024 | 2414 | 0.200 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6828 | 0.200 |
Why?
|
Cystadenocarcinoma | 1 | 2001 | 54 | 0.200 |
Why?
|
WT1 Proteins | 2 | 2021 | 184 | 0.200 |
Why?
|
Child | 29 | 2024 | 79806 | 0.190 |
Why?
|
Vulvar Diseases | 1 | 2021 | 62 | 0.190 |
Why?
|
Melanoma-Specific Antigens | 1 | 2020 | 74 | 0.180 |
Why?
|
Angiomyoma | 2 | 1997 | 10 | 0.180 |
Why?
|
Cross Infection | 4 | 2012 | 1434 | 0.180 |
Why?
|
Strongyloides stercoralis | 2 | 2001 | 23 | 0.180 |
Why?
|
Strongyloidiasis | 2 | 2001 | 27 | 0.180 |
Why?
|
Mixed Tumor, Mullerian | 2 | 2017 | 55 | 0.170 |
Why?
|
Fibrosarcoma | 1 | 2022 | 308 | 0.170 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2001 | 430 | 0.170 |
Why?
|
Itraconazole | 1 | 2000 | 43 | 0.170 |
Why?
|
Child, Preschool | 18 | 2016 | 42063 | 0.170 |
Why?
|
Neprilysin | 1 | 2003 | 472 | 0.170 |
Why?
|
DNA Copy Number Variations | 6 | 2020 | 2013 | 0.170 |
Why?
|
Carcinoma, Small Cell | 2 | 2015 | 416 | 0.170 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2001 | 232 | 0.170 |
Why?
|
Tissue Array Analysis | 4 | 2015 | 551 | 0.170 |
Why?
|
Nervous System Diseases | 1 | 2010 | 1647 | 0.170 |
Why?
|
Peritoneal Neoplasms | 3 | 2016 | 707 | 0.170 |
Why?
|
Research Report | 1 | 2022 | 370 | 0.160 |
Why?
|
Saliva | 1 | 2003 | 820 | 0.160 |
Why?
|
Mullerian Ducts | 2 | 2018 | 201 | 0.160 |
Why?
|
Lung Diseases, Fungal | 1 | 1999 | 126 | 0.160 |
Why?
|
Tumor Burden | 2 | 2016 | 1895 | 0.160 |
Why?
|
Cell Nucleus | 4 | 2016 | 2907 | 0.160 |
Why?
|
DNA Polymerase II | 1 | 2019 | 104 | 0.160 |
Why?
|
Hyperplasia | 3 | 2017 | 1155 | 0.150 |
Why?
|
Fibroma | 1 | 2000 | 190 | 0.150 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3707 | 0.150 |
Why?
|
Vulva | 3 | 2023 | 82 | 0.150 |
Why?
|
Cysteine | 1 | 2022 | 895 | 0.150 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 429 | 0.150 |
Why?
|
Plant Lectins | 1 | 1997 | 103 | 0.150 |
Why?
|
Nasal Cavity | 1 | 1999 | 304 | 0.150 |
Why?
|
Epithelial Cells | 3 | 2018 | 3663 | 0.150 |
Why?
|
Lung Neoplasms | 6 | 2019 | 13262 | 0.140 |
Why?
|
PTEN Phosphohydrolase | 5 | 2024 | 1115 | 0.140 |
Why?
|
Tandem Repeat Sequences | 1 | 2018 | 180 | 0.140 |
Why?
|
Mediator Complex | 2 | 2018 | 106 | 0.140 |
Why?
|
GTP Phosphohydrolases | 2 | 2017 | 518 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2020 | 8515 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 10 | 2019 | 17790 | 0.140 |
Why?
|
Gynecologic Surgical Procedures | 2 | 2015 | 304 | 0.140 |
Why?
|
Opportunistic Infections | 2 | 2000 | 377 | 0.140 |
Why?
|
Angiofibroma | 1 | 1997 | 55 | 0.140 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2017 | 199 | 0.140 |
Why?
|
Gene Duplication | 1 | 2018 | 313 | 0.140 |
Why?
|
Receptors, Estrogen | 4 | 2023 | 2210 | 0.140 |
Why?
|
Fatal Outcome | 3 | 2013 | 1832 | 0.140 |
Why?
|
Candidiasis, Invasive | 1 | 2016 | 23 | 0.140 |
Why?
|
Bowen's Disease | 1 | 1996 | 13 | 0.140 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2020 | 346 | 0.130 |
Why?
|
Sarcoma, Small Cell | 1 | 2016 | 17 | 0.130 |
Why?
|
Cell Lineage | 3 | 2024 | 2533 | 0.130 |
Why?
|
Genomic Instability | 1 | 2020 | 704 | 0.130 |
Why?
|
Fat Emulsions, Intravenous | 1 | 1999 | 314 | 0.130 |
Why?
|
Condylomata Acuminata | 1 | 1996 | 75 | 0.130 |
Why?
|
Repressor Proteins | 2 | 2018 | 2981 | 0.130 |
Why?
|
Mesonephroma | 1 | 2015 | 21 | 0.130 |
Why?
|
Rhabdoid Tumor | 1 | 2018 | 210 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 4 | 2019 | 2828 | 0.130 |
Why?
|
Hemangiosarcoma | 1 | 1998 | 216 | 0.130 |
Why?
|
Survival Rate | 9 | 2020 | 12808 | 0.130 |
Why?
|
STAT6 Transcription Factor | 1 | 2016 | 193 | 0.130 |
Why?
|
Anus Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2012 | 419 | 0.130 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 27 | 0.130 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1077 | 0.120 |
Why?
|
Survival Analysis | 6 | 2013 | 10182 | 0.120 |
Why?
|
Cohort Studies | 6 | 2022 | 41335 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 317 | 0.120 |
Why?
|
Desmin | 2 | 2007 | 99 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 2 | 2018 | 4490 | 0.120 |
Why?
|
Fluconazole | 1 | 2015 | 155 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2023 | 1130 | 0.120 |
Why?
|
Cerebellum | 1 | 2021 | 1496 | 0.120 |
Why?
|
Male | 43 | 2024 | 359744 | 0.120 |
Why?
|
Vascular Neoplasms | 1 | 2016 | 167 | 0.120 |
Why?
|
Time Factors | 6 | 2018 | 40165 | 0.120 |
Why?
|
Gene Expression Profiling | 7 | 2019 | 9411 | 0.120 |
Why?
|
Immunoenzyme Techniques | 4 | 2007 | 1705 | 0.110 |
Why?
|
Genes, BRCA2 | 4 | 2010 | 603 | 0.110 |
Why?
|
Sweden | 1 | 2017 | 1381 | 0.110 |
Why?
|
Deoxycholic Acid | 1 | 2013 | 53 | 0.110 |
Why?
|
In Situ Hybridization | 2 | 2016 | 1900 | 0.110 |
Why?
|
Infant | 9 | 2015 | 36060 | 0.110 |
Why?
|
Genes, BRCA1 | 4 | 2010 | 765 | 0.110 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 2007 | 310 | 0.110 |
Why?
|
Pathology | 1 | 2016 | 270 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 11712 | 0.110 |
Why?
|
Human papillomavirus 11 | 1 | 2013 | 14 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 7 | 2019 | 6544 | 0.110 |
Why?
|
Pregnancy | 7 | 2023 | 29749 | 0.110 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2015 | 635 | 0.110 |
Why?
|
Lymphatic System | 1 | 2015 | 254 | 0.110 |
Why?
|
HIV Protease | 1 | 2013 | 97 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2021 | 39261 | 0.110 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 95 | 0.110 |
Why?
|
Boston | 3 | 2017 | 9280 | 0.110 |
Why?
|
Aromatase Inhibitors | 2 | 2014 | 511 | 0.110 |
Why?
|
Risk Factors | 17 | 2017 | 74359 | 0.110 |
Why?
|
Treatment Outcome | 12 | 2019 | 65017 | 0.110 |
Why?
|
Virus Activation | 1 | 2015 | 319 | 0.110 |
Why?
|
Mesothelioma | 1 | 2019 | 807 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 916 | 0.100 |
Why?
|
Stathmin | 1 | 2013 | 70 | 0.100 |
Why?
|
Prospective Studies | 12 | 2023 | 54303 | 0.100 |
Why?
|
PAX2 Transcription Factor | 3 | 2024 | 86 | 0.100 |
Why?
|
Neoplasms | 4 | 2012 | 22072 | 0.100 |
Why?
|
Fusarium | 1 | 2012 | 51 | 0.100 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 263 | 0.100 |
Why?
|
Organoids | 1 | 2018 | 729 | 0.100 |
Why?
|
Prostate | 1 | 2000 | 1793 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2013 | 727 | 0.100 |
Why?
|
Microdissection | 2 | 2009 | 151 | 0.100 |
Why?
|
Nitriles | 2 | 2014 | 956 | 0.100 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2014 | 329 | 0.100 |
Why?
|
Sensitivity and Specificity | 8 | 2024 | 14660 | 0.100 |
Why?
|
Peritoneum | 1 | 2012 | 224 | 0.100 |
Why?
|
Kidney Transplantation | 2 | 2017 | 4215 | 0.100 |
Why?
|
Genomics | 4 | 2023 | 5794 | 0.100 |
Why?
|
Hydatidiform Mole | 2 | 2004 | 254 | 0.100 |
Why?
|
Triazoles | 2 | 2014 | 904 | 0.100 |
Why?
|
Terminology as Topic | 3 | 2018 | 1535 | 0.100 |
Why?
|
Osteosarcoma | 1 | 2017 | 897 | 0.100 |
Why?
|
Cell Differentiation | 7 | 2024 | 11481 | 0.090 |
Why?
|
Histocytochemistry | 1 | 2012 | 700 | 0.090 |
Why?
|
Hospitalization | 1 | 2011 | 10790 | 0.090 |
Why?
|
Nomograms | 1 | 2013 | 238 | 0.090 |
Why?
|
HMGA Proteins | 1 | 2010 | 7 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2015 | 719 | 0.090 |
Why?
|
Gynecology | 1 | 2016 | 528 | 0.090 |
Why?
|
Antigens, Differentiation | 1 | 2013 | 911 | 0.090 |
Why?
|
Transplantation, Autologous | 4 | 2006 | 2116 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2554 | 0.090 |
Why?
|
Zygomycosis | 1 | 2009 | 7 | 0.080 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2007 | 346 | 0.080 |
Why?
|
Polymerase Chain Reaction | 4 | 2018 | 6068 | 0.080 |
Why?
|
DNA Repair | 1 | 2018 | 2039 | 0.080 |
Why?
|
Karyotyping | 2 | 2010 | 1171 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2015 | 2932 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 609 | 0.080 |
Why?
|
Adenoma | 1 | 2019 | 2148 | 0.080 |
Why?
|
Vimentin | 2 | 2002 | 255 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1423 | 0.080 |
Why?
|
Staining and Labeling | 3 | 2007 | 1089 | 0.080 |
Why?
|
Premenopause | 1 | 2013 | 1038 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4573 | 0.080 |
Why?
|
Phenotype | 7 | 2023 | 16546 | 0.080 |
Why?
|
Membrane Proteins | 4 | 2017 | 7850 | 0.080 |
Why?
|
Omentum | 2 | 2019 | 169 | 0.080 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2013 | 217 | 0.080 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4902 | 0.080 |
Why?
|
Genetic Markers | 2 | 2012 | 2608 | 0.080 |
Why?
|
Cytogenetic Analysis | 3 | 2016 | 271 | 0.080 |
Why?
|
Endothelium | 1 | 2010 | 764 | 0.070 |
Why?
|
Drug Combinations | 1 | 2013 | 2025 | 0.070 |
Why?
|
Piperacillin | 1 | 2007 | 37 | 0.070 |
Why?
|
Estrogen Replacement Therapy | 1 | 2014 | 1206 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2015 | 1613 | 0.070 |
Why?
|
Reproducibility of Results | 9 | 2020 | 20080 | 0.070 |
Why?
|
Glucose | 1 | 1999 | 4351 | 0.070 |
Why?
|
Penicillanic Acid | 1 | 2007 | 41 | 0.070 |
Why?
|
Cardiovascular System | 1 | 2015 | 850 | 0.070 |
Why?
|
Estrogens | 1 | 2014 | 1520 | 0.070 |
Why?
|
Leukemia | 1 | 1995 | 1520 | 0.070 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2007 | 410 | 0.070 |
Why?
|
Risk Assessment | 5 | 2022 | 24123 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1894 | 0.070 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9185 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2017 | 2873 | 0.070 |
Why?
|
Intestinal Mucosa | 1 | 1997 | 3022 | 0.070 |
Why?
|
Genes, p53 | 3 | 2018 | 713 | 0.070 |
Why?
|
Glioblastoma | 1 | 2021 | 3484 | 0.070 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 693 | 0.070 |
Why?
|
Lymphoma | 1 | 1995 | 1898 | 0.070 |
Why?
|
Carbapenems | 1 | 2007 | 123 | 0.070 |
Why?
|
Microbial Sensitivity Tests | 1 | 2012 | 1949 | 0.070 |
Why?
|
Transplantation, Homologous | 1 | 2015 | 4810 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2006 | 1375 | 0.070 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2007 | 347 | 0.070 |
Why?
|
Cephalosporins | 1 | 2007 | 204 | 0.070 |
Why?
|
Embryonic Stem Cells | 2 | 2013 | 1262 | 0.070 |
Why?
|
Computational Biology | 2 | 2019 | 3505 | 0.060 |
Why?
|
Disease Progression | 4 | 2016 | 13502 | 0.060 |
Why?
|
Carboplatin | 2 | 2019 | 788 | 0.060 |
Why?
|
Nevus, Pigmented | 1 | 2008 | 221 | 0.060 |
Why?
|
Fallopian Tube Diseases | 1 | 2005 | 60 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2007 | 370 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1347 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2015 | 2001 | 0.060 |
Why?
|
Exocrine Glands | 1 | 2004 | 46 | 0.060 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1274 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6498 | 0.060 |
Why?
|
Epithelioid Cells | 1 | 2024 | 60 | 0.060 |
Why?
|
Gene Dosage | 2 | 2020 | 1218 | 0.060 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2471 | 0.060 |
Why?
|
Mastication | 1 | 2003 | 53 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4122 | 0.050 |
Why?
|
Colony-Forming Units Assay | 1 | 2003 | 351 | 0.050 |
Why?
|
Keratins | 2 | 2002 | 497 | 0.050 |
Why?
|
Cell Dedifferentiation | 1 | 2024 | 122 | 0.050 |
Why?
|
Deoxycytidine | 2 | 2018 | 873 | 0.050 |
Why?
|
Graft Rejection | 1 | 2016 | 4426 | 0.050 |
Why?
|
Exons | 2 | 2019 | 2388 | 0.050 |
Why?
|
Genitalia, Female | 1 | 2023 | 147 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Hospitals, Public | 3 | 2001 | 201 | 0.050 |
Why?
|
Sequence Analysis, DNA | 3 | 2020 | 4713 | 0.050 |
Why?
|
Europe | 2 | 2021 | 3441 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Pathology, Surgical | 1 | 2003 | 151 | 0.050 |
Why?
|
Keratin-20 | 1 | 2002 | 31 | 0.050 |
Why?
|
Chromosome Deletion | 1 | 2007 | 1387 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12531 | 0.050 |
Why?
|
Keratin-7 | 1 | 2002 | 55 | 0.050 |
Why?
|
Blotting, Western | 3 | 2015 | 5039 | 0.050 |
Why?
|
Trans-Activators | 3 | 2016 | 2860 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2022 | 169 | 0.050 |
Why?
|
Artificial Gene Fusion | 1 | 2001 | 56 | 0.050 |
Why?
|
Incidence | 2 | 2012 | 21392 | 0.050 |
Why?
|
DNA, Viral | 2 | 2020 | 2194 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2017 | 22053 | 0.050 |
Why?
|
Multivariate Analysis | 5 | 2016 | 12159 | 0.050 |
Why?
|
Intensive Care Units | 2 | 2012 | 3736 | 0.050 |
Why?
|
Receptor, trkA | 1 | 2022 | 159 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5351 | 0.050 |
Why?
|
gp100 Melanoma Antigen | 1 | 2020 | 38 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2003 | 412 | 0.050 |
Why?
|
Intermediate Filament Proteins | 1 | 2002 | 263 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2020 | 65 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2002 | 336 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18416 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2020 | 46 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2020 | 42 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2020 | 40 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2003 | 438 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 580 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 383 | 0.040 |
Why?
|
Receptors, Somatostatin | 1 | 2020 | 136 | 0.040 |
Why?
|
Alphapapillomavirus | 2 | 2013 | 218 | 0.040 |
Why?
|
Actins | 1 | 2007 | 2049 | 0.040 |
Why?
|
Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
Anti-Bacterial Agents | 2 | 2009 | 7408 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 629 | 0.040 |
Why?
|
Infant, Newborn | 4 | 2012 | 26181 | 0.040 |
Why?
|
Lymph Node Excision | 3 | 2013 | 1303 | 0.040 |
Why?
|
Length of Stay | 1 | 2012 | 6479 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5425 | 0.040 |
Why?
|
Epithelium | 2 | 2013 | 1605 | 0.040 |
Why?
|
Peanut Agglutinin | 1 | 1997 | 19 | 0.040 |
Why?
|
Fever | 2 | 2003 | 1617 | 0.040 |
Why?
|
Online Systems | 1 | 2019 | 181 | 0.040 |
Why?
|
Activated Protein C Resistance | 1 | 1998 | 18 | 0.040 |
Why?
|
Alberta | 1 | 2018 | 66 | 0.040 |
Why?
|
Exanthema | 1 | 2003 | 504 | 0.040 |
Why?
|
Mesonephros | 1 | 2017 | 42 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 1997 | 6853 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2009 | 3446 | 0.040 |
Why?
|
CA-19-9 Antigen | 1 | 1997 | 106 | 0.040 |
Why?
|
Nucleic Acid Hybridization | 1 | 2019 | 1304 | 0.040 |
Why?
|
Hodgkin Disease | 2 | 1997 | 1378 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.040 |
Why?
|
North America | 1 | 2021 | 1284 | 0.040 |
Why?
|
Matrix Attachment Region Binding Proteins | 1 | 2017 | 47 | 0.040 |
Why?
|
False Positive Reactions | 1 | 1999 | 956 | 0.040 |
Why?
|
Gangliosides | 1 | 1997 | 131 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3775 | 0.040 |
Why?
|
Mucin-1 | 1 | 2002 | 539 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2001 | 924 | 0.040 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1997 | 283 | 0.030 |
Why?
|
Introns | 1 | 2019 | 978 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2016 | 15697 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2943 | 0.030 |
Why?
|
Algorithms | 2 | 2016 | 13981 | 0.030 |
Why?
|
Vagina | 1 | 2022 | 837 | 0.030 |
Why?
|
Syndrome | 1 | 2003 | 3280 | 0.030 |
Why?
|
Alleles | 1 | 2007 | 6898 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2001 | 2852 | 0.030 |
Why?
|
Mucins | 1 | 1999 | 568 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2018 | 796 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14495 | 0.030 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2017 | 385 | 0.030 |
Why?
|
Ascariasis | 1 | 1995 | 13 | 0.030 |
Why?
|
Northern Ireland | 1 | 2015 | 37 | 0.030 |
Why?
|
Lectins | 1 | 1997 | 484 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2023 | 2005 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 580 | 0.030 |
Why?
|
International Agencies | 1 | 2016 | 244 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 2 | 2003 | 2802 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3276 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 1997 | 232 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12626 | 0.030 |
Why?
|
Schistosomiasis | 1 | 1995 | 64 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 404 | 0.030 |
Why?
|
Microfilament Proteins | 2 | 2013 | 1135 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2019 | 733 | 0.030 |
Why?
|
Genes, ras | 1 | 1997 | 655 | 0.030 |
Why?
|
Thrombophilia | 1 | 1998 | 306 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1088 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15840 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2007 | 4938 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 1998 | 673 | 0.030 |
Why?
|
Salpingectomy | 1 | 2014 | 48 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 681 | 0.030 |
Why?
|
Spain | 1 | 2015 | 488 | 0.030 |
Why?
|
Taxoids | 1 | 2017 | 669 | 0.030 |
Why?
|
Skin Neoplasms | 2 | 2008 | 5799 | 0.030 |
Why?
|
Pathology, Molecular | 1 | 2016 | 329 | 0.030 |
Why?
|
Stomach | 1 | 2017 | 694 | 0.030 |
Why?
|
Hypercalcemia | 1 | 2015 | 421 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6131 | 0.030 |
Why?
|
Colonic Polyps | 1 | 1997 | 551 | 0.030 |
Why?
|
World Health Organization | 1 | 2019 | 1312 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2015 | 16939 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1998 | 0.030 |
Why?
|
Pyrazines | 1 | 2018 | 1199 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2016 | 715 | 0.030 |
Why?
|
Drug Administration Schedule | 3 | 2013 | 4899 | 0.030 |
Why?
|
Chloride Channels | 1 | 2013 | 221 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3584 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3465 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2722 | 0.030 |
Why?
|
Cell Division | 1 | 1999 | 4463 | 0.030 |
Why?
|
Conization | 1 | 2011 | 17 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 2000 | 2693 | 0.020 |
Why?
|
Leukemia, Myeloid | 1 | 1995 | 695 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2001 | 2440 | 0.020 |
Why?
|
Administration, Oral | 1 | 2000 | 4035 | 0.020 |
Why?
|
Ovariectomy | 1 | 2014 | 611 | 0.020 |
Why?
|
Electrosurgery | 1 | 2011 | 51 | 0.020 |
Why?
|
Testicular Neoplasms | 1 | 1998 | 801 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2012 | 302 | 0.020 |
Why?
|
Protein Phosphatase 2 | 1 | 2013 | 236 | 0.020 |
Why?
|
Adenosine Triphosphatases | 1 | 2015 | 832 | 0.020 |
Why?
|
DNA Replication | 1 | 2018 | 1412 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1736 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2203 | 0.020 |
Why?
|
Databases, Protein | 1 | 2013 | 388 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 412 | 0.020 |
Why?
|
Lymph Nodes | 2 | 2013 | 3486 | 0.020 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2012 | 276 | 0.020 |
Why?
|
Formaldehyde | 1 | 2012 | 358 | 0.020 |
Why?
|
Dosage Forms | 1 | 2010 | 57 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2016 | 1110 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13630 | 0.020 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2015 | 727 | 0.020 |
Why?
|
History, 21st Century | 1 | 2016 | 1575 | 0.020 |
Why?
|
Steroids | 1 | 1995 | 928 | 0.020 |
Why?
|
Biochemical Phenomena | 1 | 2010 | 58 | 0.020 |
Why?
|
Adipocytes | 1 | 1997 | 1179 | 0.020 |
Why?
|
Graft Survival | 2 | 2016 | 3794 | 0.020 |
Why?
|
Mast Cells | 1 | 1997 | 1390 | 0.020 |
Why?
|
Cell Polarity | 1 | 2013 | 638 | 0.020 |
Why?
|
Genes, p16 | 1 | 2010 | 159 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2013 | 657 | 0.020 |
Why?
|
Bleomycin | 2 | 2006 | 495 | 0.020 |
Why?
|
Food Microbiology | 1 | 2009 | 76 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2001 | 4541 | 0.020 |
Why?
|
Apoptosis | 2 | 2020 | 9501 | 0.020 |
Why?
|
Gene Silencing | 1 | 2015 | 1513 | 0.020 |
Why?
|
Drug Resistance, Fungal | 1 | 2009 | 73 | 0.020 |
Why?
|
Urate Oxidase | 1 | 1988 | 31 | 0.020 |
Why?
|
History, 20th Century | 1 | 2016 | 2773 | 0.020 |
Why?
|
Vincristine | 2 | 2006 | 1039 | 0.020 |
Why?
|
Intestines | 1 | 2017 | 1907 | 0.020 |
Why?
|
Doxorubicin | 3 | 2006 | 2209 | 0.020 |
Why?
|
Pyrazoles | 1 | 2018 | 1999 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2821 | 0.020 |
Why?
|
Pelvic Pain | 1 | 2010 | 298 | 0.020 |
Why?
|
United States | 5 | 2018 | 72461 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 2180 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 10827 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 2013 | 1343 | 0.020 |
Why?
|
DNA Damage | 2 | 2008 | 2442 | 0.020 |
Why?
|
SEER Program | 1 | 2012 | 1530 | 0.020 |
Why?
|
Italy | 1 | 2009 | 841 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3568 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4550 | 0.020 |
Why?
|
DNA | 1 | 2020 | 7233 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3905 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3113 | 0.020 |
Why?
|
Cryosurgery | 1 | 2011 | 475 | 0.020 |
Why?
|
Cyclin E | 1 | 2007 | 155 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1433 | 0.020 |
Why?
|
Prednisone | 2 | 2006 | 1565 | 0.020 |
Why?
|
Protein Transport | 1 | 2012 | 1964 | 0.020 |
Why?
|
Menopause | 1 | 2014 | 1640 | 0.020 |
Why?
|
Random Allocation | 1 | 2010 | 2394 | 0.020 |
Why?
|
Prolapse | 1 | 2005 | 63 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2000 | 12427 | 0.020 |
Why?
|
Remission Induction | 2 | 2006 | 2392 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2514 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 36290 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3817 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2006 | 2221 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2004 | 43 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5785 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2012 | 17624 | 0.010 |
Why?
|
Food | 1 | 2009 | 771 | 0.010 |
Why?
|
Animals | 6 | 2020 | 167963 | 0.010 |
Why?
|
Specimen Handling | 1 | 2009 | 707 | 0.010 |
Why?
|
Etoposide | 1 | 2006 | 630 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 2009 | 643 | 0.010 |
Why?
|
Incidental Findings | 1 | 2009 | 698 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2717 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2013 | 6216 | 0.010 |
Why?
|
Reoperation | 1 | 2013 | 4291 | 0.010 |
Why?
|
Genotype | 1 | 1997 | 12960 | 0.010 |
Why?
|
Odds Ratio | 1 | 1995 | 9716 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6965 | 0.010 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 854 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 1988 | 1189 | 0.010 |
Why?
|
Mice | 3 | 2020 | 81208 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2003 | 25942 | 0.010 |
Why?
|
Ovary | 1 | 2007 | 958 | 0.010 |
Why?
|
Uric Acid | 1 | 1988 | 806 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8313 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2004 | 786 | 0.010 |
Why?
|
DNA Methylation | 1 | 2016 | 4373 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8950 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2015 | 3598 | 0.010 |
Why?
|
Antibodies, Helminth | 1 | 2001 | 57 | 0.010 |
Why?
|
Antigens, Helminth | 1 | 2001 | 68 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 18957 | 0.010 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 2001 | 113 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7475 | 0.010 |
Why?
|
Hospitals | 1 | 2015 | 3928 | 0.010 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2001 | 122 | 0.010 |
Why?
|
Keratin-14 | 1 | 2001 | 56 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2007 | 1602 | 0.010 |
Why?
|
Splenic Neoplasms | 1 | 2001 | 95 | 0.010 |
Why?
|
Blotting, Southern | 1 | 2001 | 777 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15789 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9335 | 0.010 |
Why?
|
Hospitals, University | 1 | 2001 | 568 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4417 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7593 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2008 | 1889 | 0.010 |
Why?
|
Cell Survival | 1 | 2007 | 5797 | 0.010 |
Why?
|
Cancer Care Facilities | 1 | 2000 | 424 | 0.010 |
Why?
|
Menstrual Cycle | 1 | 2001 | 536 | 0.010 |
Why?
|
Factor V | 1 | 1998 | 168 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1988 | 1628 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4000 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9631 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2001 | 1055 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2001 | 1871 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 1999 | 11345 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2001 | 1745 | 0.010 |
Why?
|
Aminoglutethimide | 1 | 1995 | 13 | 0.010 |
Why?
|
Carbenicillin | 1 | 1995 | 15 | 0.010 |
Why?
|
Cephalothin | 1 | 1995 | 35 | 0.010 |
Why?
|
Community-Acquired Infections | 1 | 1999 | 461 | 0.010 |
Why?
|
Amikacin | 1 | 1995 | 48 | 0.010 |
Why?
|
Danazol | 1 | 1995 | 45 | 0.010 |
Why?
|
Ceftazidime | 1 | 1995 | 57 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1998 | 402 | 0.010 |
Why?
|
Feces | 1 | 2001 | 1455 | 0.010 |
Why?
|
Daunorubicin | 1 | 1995 | 156 | 0.010 |
Why?
|
Life Tables | 1 | 1995 | 365 | 0.010 |
Why?
|
Urban Health | 1 | 1997 | 533 | 0.010 |
Why?
|
Brain | 1 | 2021 | 26951 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3804 | 0.010 |
Why?
|
Blood Component Transfusion | 1 | 1995 | 141 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3925 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 1999 | 1630 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2013 | 18137 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 15620 | 0.010 |
Why?
|
Procarbazine | 1 | 1993 | 172 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1993 | 129 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1997 | 1600 | 0.010 |
Why?
|
Cytarabine | 1 | 1995 | 696 | 0.010 |
Why?
|
Urban Population | 1 | 2001 | 2022 | 0.010 |
Why?
|
Hematopoiesis | 1 | 2002 | 2050 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5075 | 0.010 |
Why?
|
Vinblastine | 1 | 1993 | 487 | 0.010 |
Why?
|
Bone Marrow | 1 | 2001 | 2912 | 0.010 |
Why?
|
Tamoxifen | 1 | 1995 | 963 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12446 | 0.010 |
Why?
|
Prostatectomy | 1 | 1999 | 1956 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2001 | 13451 | 0.010 |
Why?
|
Melanoma | 1 | 2008 | 5697 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 1999 | 2529 | 0.010 |
Why?
|
Linear Models | 1 | 1999 | 5877 | 0.000 |
Why?
|
Salvage Therapy | 1 | 1995 | 1268 | 0.000 |
Why?
|
Infection Control | 1 | 1995 | 983 | 0.000 |
Why?
|
Injections, Intramuscular | 1 | 1988 | 553 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8552 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 2001 | 4319 | 0.000 |
Why?
|
Prevalence | 1 | 2001 | 15687 | 0.000 |
Why?
|
Acute Disease | 1 | 1995 | 7269 | 0.000 |
Why?
|
Primary Health Care | 1 | 1995 | 4647 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1988 | 2093 | 0.000 |
Why?
|
Health Services Accessibility | 1 | 1995 | 5397 | 0.000 |
Why?
|